DETECTION OF HUMAN PAPILLOMAVIRUS GENOTYPES BY PYROSEQUENCING METHOD

Abstract

Human papillomavirus (HPV) is the primary cause of cervical cancer and is identified in approximately 100% of cases. The aim of this study was to detect HPV genotypes by pyrosequencing method among women attending the Department of Gynecology, Faculty of Medicine, University. Cervical cytology samples were collected from 1145 women aged 20-65 years old. HPV Sign PQ genotyping test (Diatech Pharmacogenetics, Italy) based on pyrosequencing method was used for HPV genotyping. Pyrosequencing was performed on PyroMark Q24 instrument (Qiagen). The prevalence of HPV infection was 20% (229) in total 1145 women. Single HPV infection and multiple HPV infection was found in 11.8% (136) and 8.2% (93) of the study population, respectively. HPV 16 was the most prevalent HPV genotype (9.4%), followed by HPV 18 (4.8%), HPV 56 (4%), HPV 51 (2.5%), HPV 33 (2.2%), HPV 39 (1.9%), HPV 31 (1.7%), HPV 35 (1.7%), HPV 58 (1.1%), HPV 59 (0.9%), HPV 68 (0.5%), HPV 45 (0.4%), HPV 66 (0.4%) and HPV 52 (0.2%). In conclucions, this study we conducted in our region based on hospitals is the most comprehensive study ever made up to 1145 participants HPV 16 and HPV 18 found as the most common HPV types are targeted by prophylactic HPV vaccines. 

Keywords

• HPV,genotip,pyrosequencing,servikal kanser,tarama

HUMAN PAPİLLOMAVİRUS GENOTİPLERİNİN PYROSEQUENCİNG METODU İLE TESPİTİ

Abstract

Human papillomavirus (HPV) servikal kanserin primer sebebidir ve vakaların yaklaşık %100’ünde bulunur. Bu çalışmanın amacı Çukurova Üniversitesi, Tıp Fakültesi, Jinekoloji bölümüne başvuran kadınlarda yüksek risk HPV genotiplerinin pyrosequencing metodu ile tespitidir. Servikal sitoloji örnekleri 20-65 yaş arasındaki 1145 kadından toplanmıştır. HPV genotiplemesi için pyrosequencing metoduna dayanan HPV Sign PQ genotipleme testi (Diatech Pharmacogenetics, Italy) kullanılmıştır. Pyrosequencing PyroMark Q24 cihazında (Qiagen) yapılmıştır. HPV enfeksiyonunun prevalansı toplam 1145 kadında %20 (229) idi. Tek HPV enfeksiyonu ve çoklu HPV enfeksiyonu sırasıyla, çalışma grubunun %11.8’inde (136) ve %8.2’inde (93) bulunmuştur. En baskın HPV genotipi HPV 16 (%9.4) olup bunu HPV 18 (%4.8) HPV 56 (%4), HPV 51 (%2.5), HPV 33 (%2.2), HPV 39 (%1.9), HPV 31 (%1.7), HPV 35 (%1.7), HPV 58 (%1.1), HPV 59 (%0.9), HPV 68 (%0.5), HPV 45 (%0.4), HPV 66 (%0.4) ve HPV 52 (%0.2) izlemiştir. Sonuç olarak, bölgemizde hastane bazlı yaptığımız bu çalışma 1145 kişinin katıldığı şimdiye kadar yapılan en kapsamlı çalışma olup en yaygın HPV tipleri olarak bulunan HPV 16 ve HPV 18 profilaktik HPV aşılarının hedefidir. Yeni jenerasyon dizi analizi metodu olan pyrosequencing test ile HPV genotiplerinin tanısı servikal kanser için risk altındaki kadınların tespitine katkı sağlayacaktır. 

Keywords

• HPV,genotip,pyrosequencing,servikal kanser,tarama

References

1. 1. Walhart T.J. Human Papillomavirus Biology, Pathogenesis, and Potential for Drug Discovery: A Literature Review for HIV Nurse Clinical Scientists. Assoc Nurses AIDS Care. 2015; 26(6):693-702.
2. 2. Comparetto C, Borruto F. Cervical cancer screening: A never-ending developing program. World J Clin Cases. 2015;3(7): 614–624.
3. 3. Fernandes JV, Fernandes TA. Human Papillomavirus: Biology and Pathogenesis. Human Papillomavirus and Related Diseases – From Bench to Bedside– A Clinical Perspective. In Tech 2012 DOI: 10.5772/2464.
4. 4. Egawa N, Egawa K, Griffin H, Doorbar J. Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia. Viruses. 2015;7(7):3863-90.
5. 5. Bansal A, Singh MP, Rai B. Human papillomavirus-associated cancers: A growing global problem. Int J Appl Basic Med Res. 2016; 6(2):84-9.
6. 6. Lees BF, Erickson BK, Huh WK. Cervical cancer screening: evidence behind the guidelines. Am J Obstet Gynecol. 2016; 214(4):438-43.
7. 7. Moreira ED Jr, Block SL, Ferris D, et al. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III. Clinical Trials. 2016;138(2)..
8. 8. Yuce K, Pinar A, Salman MC, ve ark. Detection and genotyping of cervical HPV with simultaneous cervical cytology in Turkish women: a hospital-based study. Arch Gynecol Obstet. 2012; 286(1):203-8.

9. 9. Sahiner F, Gümral R, Sener K,ve ark. Investigation of HPV-DNA in cervical smear samples by two different methods: MY09/11 consensus PCR and type-specific real-time PCR. Mikrobiyol Bul. 2012; 46(4):624-36.
10. 10. Tezcan S, Ozgur D, Ulger M, ve ark. Human papillomavirus genotype distribution and E6/E7 oncogene expression in Turkish women with cervical cytological findings. Asian Pac J Cancer Prev. 2014; 15(9):3997-4003.
11. 11. Fındık D. Türk Dağı H. Arslan U. Fındık Y. Servikal örneklerde human papillomavirus sıklığı ve genotip dağılı- mı Genel Tıp Derg 2012; 22(4):116-20.
12. 12. Şahiner F, Kubar A, Gümral R, ve ark. Efficiency of MY09/11 consensus PCR in the detection of multiple HPV infections. Diagn Microbiol Infect Dis. 2014; 80(1):43-9.
13. 13. Demir ET, Ceyhan M, Simsek M, ve ark. The prevalence of different HPV types in Turkish women with a normal Pap smear. J Med Virol. 2012; 84(8):1242-7.
14. 14. Tüney İ, Altay A, Ergünay K, ve ark. HPV tyes and E6/ E7 mRNA expression in cervical samples from Turkish women with abnormal cytology in Ankara, Turkey. Turk J Med Sci. 2017; 47: 194-200.
15. 15. Santos Filho MV, Gurgel AP, Lobo CD, Freitas AC, SilvaNeto JC, Silva LA. Prevalence of human papillomavirus (HPV), distribution of HPV types, and risk factors for infection in HPV-positive women. Genet Mol Res. 2016; 14;15(2).
16. 16. Meloni A, Pilia R, Campagna M, et al. Prevalence and molecular epidemiology of human papillomavirus infection in italian women with cervical cytological abnormalities. J Public Health Res. 2014 ;3(1):157.
17. 17. Grozdanov P, Zlatkov V, Ganchev G, Karagiosov I, Toncheva D, Galabov AS. HPV prevalence and type distribution in women with normal or abnormal Pap smear in Bulgaria. J Med Virol. 2014; 86(11):1905-10.
18. 18. Salcedo M, Pina-Sanchez P, Vallejo-Ruiz V, et al. Human papillomavirus genotypes among females in Mexico a study from the Mexicaninstitute for social security. Asian Pac J Cancer Prev. 2014; 15(23):10061-6.
19. 19. Yousefzadeh A, Mostafavizadeh SM, Jarollahi A, et al. Human papillomavirus (HPV) prevalence and types among women attending regular gynecological visit in Tehran. Iran. Clin Lab. 2014; 60(2):267-73.
20. 20. Moga MA, Irimie M, Oanta A, Pascu A, Burtea V. Typespecific prevalence of human papillomavirus by cervical cytology among women in Brasov, Romania. Asian Pac J Cancer Prev. 2014; 15(16):6887-92
21. 21. Lewis-Bell K, Luciani S, Unger ER, et al. Genital human papillomaviruses among women of reproductive age in Jamaica. Rev Panam Salud Publica. 2013; 33(3):159-65.
22. 22. Lindemann ML, Sánchez Calvo JM, Chacón de Antonio J, et al. Prevalence and Distribution of High-Risk Genotypes of HPV in Women with Severe Cervical Lesions in Madrid, Spain: Importance of Detecting Genotype 16 and Other High-Risk Genotypes. Adv Prev Med. 2011;
23. 23. De Jonge M, Busecke G, Heinecke A, Bettendorf O. Human papillomavirus genotype distribution in cytologically screened women from northwest Germany. Acta Cytol. 2013; 57(6):591-8.
24. 24. Heard I, Tondeur L, Arowas L, Falguières M, Demazoin MC, Favre M. Human papillomavirus types distribution in organised cervical cancer screening in France. PLoS One. 2013 14;8(11).
25. 25. Aguilar-Lemarroy A, Vallejo-Ruiz V, Cortés-Gutiérrez EI, et al. Human papillomavirus infections in Mexican women with normal cytology, precancerous lesions, and cervical cancer: type-specific prevalence and HPV coinfections. J Med Virol. 2015; 87(5):871-84.